How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

OBJECTIVE: We aimed to study the epidemiology of the prodromal and mild stages of Alzheimer’s disease (AD) patients who are eligible for clinical trials with disease-modifying therapies. SETTINGS: We analysed two large complementary databases to study the incidence and characteristics of this popula...

Descripción completa

Detalles Bibliográficos
Autores principales: Epelbaum, Stéphane, Paquet, Claire, Hugon, Jacques, Dumurgier, Julien, Wallon, David, Hannequin, Didier, Jonveaux, Thérèse, Besozzi, Annick, Pouponneau, Stéphane, Hommet, Caroline, Blanc, Frederic, Berly, Laetitia, Julian, Adrien, Paccalin, Marc, Pasquier, Florence, Bellet, Julie, Boutoleau-Bretonniere, Claire, Charriau, Thiphaine, Rouaud, Olivier, Madec, Olivier, Mouton, Aurélie, David, Renaud, Bekadar, Samir, Fabre, Roxane, Liegey, Emmanuelle, Deberdt, Walter, Robert, Philippe, Dubois, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597622/
https://www.ncbi.nlm.nih.gov/pubmed/31239309
http://dx.doi.org/10.1136/bmjopen-2019-029663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597622/
https://www.ncbi.nlm.nih.gov/pubmed/31239309
http://dx.doi.org/10.1136/bmjopen-2019-029663

Ejemplares similares